To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally advanced and metastatic adenocarcinoma of the pancreas.
The trial is a Phase III, multinational, multicentre, controlled, randomised open-label trial. It will involve 520 advanced pancreatic cancer patients. Patients will be randomly assigned to receive Gemcitabine alone or GV1001 plus GM-CSF followed by addition of Gemcitabine at the time of 1st progression of disease. The experimental treatment is given prior to the current standard treatment in 50% of the patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
360
0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
Overall survival time
Time frame: 12 month
Progression Free Survival
Time frame: Time of progression
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
Scripps Clinic Torrey Pines
La Jolla, California, United States
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California, United States
The Center for Hematology-Oncology
Boca Raton, Florida, United States
Tampa General Hospital Usf Digestive Disorders Centre
Tampa, Florida, United States
Palm Beach Cancer Institute
West Palm Beach, Florida, United States
Portneuf Cancer Center
Pocatello, Idaho, United States
Oncology Hematology Associates of Central Illinois, PC
Peoria, Illinois, United States
Hematology Oncology Specialists, Covington
Covington, Louisiana, United States
...and 76 more locations